GP · addiction-medicine
Opioid dependence treatment
Also known as Opioid substitution therapy · OST · Medication-assisted treatment · MAT · Buprenorphine · Methadone
GP-fellowship guide to opioid dependence treatment: opioid agonist treatment (methadone and buprenorphine-naloxone) with mortality reduction evidence from systematic reviews, retention rates, take-home naloxone for overdose prevention, the GP role in prescribing and shared care, and harm reduction approaches including supervised injecting.
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Methadone induction carries almost double the all-cause mortality risk in the first four weeks — monitor closely and start low
- All-cause mortality is six times higher in the four weeks after opioid agonist treatment cessation — plan cessation carefully or avoid it
- Take-home naloxone should be offered to every patient at risk of opioid overdose, including all patients prescribed opioids for chronic pain
Overview
Opioid dependence is a chronic relapsing condition with elevated mortality. Opioid agonist treatment (OAT) — methadone or buprenorphine-naloxone — is the most effective intervention, reducing all-cause mortality by more than half during treatment. The systematic review by Santo et al. (15 RCTs, 36 cohort studies, 749,634 participants) provides the definitive evidence: OAT halves all-cause mortality (RR 0.47) with consistent benefit across sex, age, geography, HIV and hepatitis C status, and whether drugs are injected or not.[1]
References6ShowHide
- [1]Santo T Jr, Clark B, Hickman M et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA psychiatry, 2021.PMID 34076676
- [2]Sordo L, Barrio G, Bravo MJ et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ (Clinical research ed.), 2017.PMID 28446428
- [3]Klimas J, Hamilton MA, Gorfinkel L et al. Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials. Systematic reviews, 2021.PMID 34362464
- [4]Malta M, Varatharajan T, Russell C et al. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review. PLoS medicine, 2019.PMID 31891578
- [5]Miller L Bridging Emergency and Prevention: A Systematic Review of Take-Home Naloxone Programs. Journal of addictions nursing, 2025.PMID 40846320
- [6]Fraeyman J, Symons L, Van Royen P et al. How to overcome hurdles in opiate substitution treatment? A qualitative study with general practitioners in Belgium. The European journal of general practice, 2016.PMID 26799738